Nephrol Dial Transplant (2001) 16: 2-8
© 2001 European Renal Association-European Dialysis and Transplant Association
Anaemia in end-stage renal disease: pathophysiological considerations
Department of Nephrology and Medical Intensive Care, Humboldt University, Berlin, Germany
Abstract
Anaemia is a frequent complication of many diseases but the mechanisms that link reduced blood oxygen content to the long-term consequences of anaemia are incompletely understood. The maintenance of oxygen supply to the tissues during anaemia involves complex cardiovascular adaptations, including an increase in cardiac output, reduced peripheral resistance and increased oxygen extraction from haemoglobin (Hb). In addition, hypoxia-inducible factors are associated with the transcriptional activation of genes involved in adaptive mechanisms that increase oxygen delivery and provide alternative metabolic pathways. The complex pathophysiology of chronic kidney disease alters the adaptations to anaemia in uraemic patients. The increased cardiac output induced by anaemia is associated with left ventricular hypertrophy and cardiac disease in renal patients. Alterations in endothelial cell function, common in renal disease, may diminish endothelium-induced vasodilatation, increase the risk of atherosclerosis and impair angiogenesis. Many potential reasons for erythropoietin-induced hypertension in uraemic patients have been postulated, including increased blood viscosity as haematocrit rises, a reversal of hypoxic vasodilatation, increased blood volume that is not compensated by haemodialysis, ultrafiltration and impaired nitric oxide synthesis, preventing vascular relaxation in response to increased blood viscosity. In view of this impaired vascular reactivity, rapid increases in haematocrit should be avoided during epoetin treatment. As the interaction between anaemia and uraemia is very complex, it is not possible to derive the optimal Hb concentration for individual patients by using simple physiological or pathophysiological models and there is a need for good randomized controlled clinical trials to address this issue.
Keywords: anaemia; endothelial cell dysfunction; angiogenesis; hypoxia-inducible factor-1; nitric oxide; renal disease
Notes
Correspondence and offprint requests to: Dr Kai-Uwe Eckardt, Department of Nephrology and Medical Intensive Care, Charité, Campus Virchow Klinikum, Humboldt University, Augustenberger, Platz 1, D-13353, Berlin, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Husemann, M. Fobker, M. Pohlen, C. Bruch, M. Hausberg, G. Breithardt, and H. Reinecke Impact of haemoglobin concentration and chronic kidney disease in patients with coronary heart disease undergoing percutaneous coronary interventions Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2563 - 2570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wu, M. H. Noyan Ashraf, M. Facci, R. Wang, P. G. Paterson, A. Ferrie, and B. H. J. Juurlink Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system PNAS, May 4, 2004; 101(18): 7094 - 7099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Cediel, D. Sanz-Rosa, M. P. Oubina, N. de las Heras, F. R. G. Pacheco, O. Vegazo, J. Jimenez, V. Cachofeiro, and V. Lahera Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function? Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R674 - R681. [Abstract] [Full Text] [PDF]
|
|